Skip to main content

Table 1 Demographics and HRQOL/clinical findings of the study participants (n = 122)

From: Validation of the japanese version of the sarcoidosis health questionnaire: A cross-sectional study

 

Mean ± SD or n (%)

Range

Age, years

56.8 ± 15.5

24 - 85

Female

74 (60.6%)

 

Duration of sarcoidosis (months)

108.9 ± 86.2

2 - 395

Number of organ systems involved

1.8 ± 0.8

1 - 5

Radiographic stage

37/32/33/15/5

 

(0/I/II/III/IV)

(30.3%/26.2%/27.0%/12.3%/4.1%)

Blood laboratory tests

  

   ACE, IU/L

17.2 ± 6.5

3.8 - 41.7

   sIL-2R, IU/mL

639.9 ± 507.5

128 - 3772

Pulmonary function tests

  

   FVC, %predicted

105.8 ± 18.5

44.3 - 146.4

   FEV1, %predicted

105.8 ± 21.0

35.0 - 158.7

   DLCO, %predicted

85.1 ± 17.2

33.7 - 133.3

Echocardiogram

  

   LVEF, %

68.1 ± 11.4

31.8 - 79.5

   PASP, mmHg

29.4 ± 5.9

19.0 - 57.4

SHQ

  

   Daily Functioning [17]

4.7 ± 1.0

2.1 - 6.7

   Physical Functioning [17]

5.4 ± 1.0

2.7 - 6.8

   Emotional Functioning [17]

4.8 ± 1.0

2.2 - 6.9

   Total [17]

4.9 ± 0.9

2.4 - 6.7

SF-36

  

   Physical functioning [0-100]

79.2 ± 20.9

0 - 100

   Role-physical [0-100]

77.1 ± 27.0

0 - 100

   Bodily pain [0-100]

71.9 ± 26.7

0 - 100

   General health perceptions [0-100]

50.0 ± 19.7

0 - 97

   Vitality [0-100]

52.2 ± 23.1

0 - 100

   Social functioning [0-100]

78.6 ± 24.1

0 - 100

   Role-emotional [0-100]

77.7 ± 25.7

0 - 100

   Mental health [0-100]

66.6 ± 20.5

5 - 100

SGRQ

  

   Symptoms [0-100]

39.8 ± 20.6

0 - 86.5

   Activity [0-100]

29.7 ± 24.9

0 - 92.5

   Impact [0-100]

14.6 ± 14.6

0 - 57.3

   Total [0-100]

23.4 ± 16.3

0 - 71.8

MRC [15]

1.8 ± 0.8

1 - 5

CES-D [0-60]

12.8 ± 9.3

0 - 45

  1. The numbers in square brackets represent the theoretical score range.
  2. On the SHQ and SF-36, higher scores indicate better status, while on the SGRQ, MRC, CES-D, lower scores indicate better status.
  3. Abbreviations: HRQOL, health-related quality of life; SD, standard deviation; ACE, angiotensin-converting enzyme; sIL-2R, soluble interleukin-2 receptor; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; DLCO, diffusion capacity for carbon monoxide; LVEF, left ventricular ejection fraction; PASP, pulmonary arterial systolic pressure SHQ, Sarcoidosis Health Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St. George's Respiratory Questionnaire; MRC, Medical Research Council; CES-D, Center for Epidemiologic Study-Depression Scale